Structure Therapeutics (NASDAQ:GPCR) Now Covered by Analysts at William Blair

William Blair began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report sent to investors on Friday, Marketbeat reports. The firm issued an outperform rating on the stock.

A number of other equities research analysts also recently commented on GPCR. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics currently has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Up 4.1 %

GPCR stock opened at $23.75 on Friday. The company has a market cap of $1.36 billion, a P/E ratio of -32.09 and a beta of -2.75. Structure Therapeutics has a twelve month low of $19.61 and a twelve month high of $62.74. The business has a fifty day moving average of $26.58 and a 200-day moving average of $33.59.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, equities research analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock valued at $1,985,000 after acquiring an additional 312 shares during the period. Virtus ETF Advisers LLC grew its stake in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock valued at $61,000 after acquiring an additional 455 shares during the period. ANTIPODES PARTNERS Ltd grew its stake in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after acquiring an additional 553 shares during the period. LPL Financial LLC grew its stake in Structure Therapeutics by 6.0% in the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company’s stock valued at $311,000 after acquiring an additional 646 shares during the period. Finally, Assetmark Inc. grew its stake in Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after acquiring an additional 719 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.